Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
179 hedge funds and large institutions have $1.81B invested in Acorda Therapeutics in 2014 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 55 increasing their positions, 68 reducing their positions, and 20 closing their positions.
156% more call options, than puts
Call options by funds: $12.9M | Put options by funds: $5.04M
30% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 20
19% more capital invested
Capital invested by funds: $1.52B → $1.81B (+$293M)
3% more funds holding
Funds holding: 174 → 179 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
19% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 68
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$18.8M |
| 2 |
VAM
Visium Asset Management
New York
|
+$18.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.86M |
| 4 |
Charles Schwab
San Francisco,
California
|
+$7.87M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$7.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$29.3M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$12.6M |
| 3 |
MACM
March Altus Capital Management
Greenwich,
Connecticut
|
-$10.3M |
| 4 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
-$9.32M |
| 5 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$6.48M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Envestnet Asset Management
Chicago,
Illinois
| – | -$7K | -2 | Closed |
|
|
PTC
202
Private Trust Company
Cleveland,
Ohio
| – | -$1K | – | – |
|
ACOR Hedge Fund Activity: Q4 2014 in Review
179 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2014, worth a combined $1.81B — up 19% from $1.52B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ACOR positions and 20 closed out — a net gain of 6 holders — while 55 added to existing stakes and 68 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $18.8M. The largest seller was Oracle Investment Management, cutting an estimated $29.3M.
- 179 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2014, up from 174 in Q3 2014.
- Funds reported $1.81B of Acorda Therapeutics stock for Q4 2014, up 19% quarter-over-quarter.
- 26 funds opened new Acorda Therapeutics positions in Q4 2014 and 20 closed out, a net change of +6 holders.
- The largest Acorda Therapeutics buyer in Q4 2014 was Wellington Management Group, an estimated $18.8M added.
- The largest Acorda Therapeutics seller in Q4 2014 was Oracle Investment Management, an estimated $29.3M sold.
Based on aggregated 13F filings for Q4 2014.